Last reviewed · How we verify
Moxifloxacin and Dexamethasone combined — Competitive Intelligence Brief
phase 3
Fluoroquinolone antibiotic + Corticosteroid combination
Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone)
Infectious Disease / Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Moxifloxacin and Dexamethasone combined (Moxifloxacin and Dexamethasone combined) — Federal University of São Paulo. Moxifloxacin (a fluoroquinolone antibiotic) inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone (a corticosteroid) suppresses inflammation and immune response.
Comparator set (4 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Moxifloxacin and Dexamethasone combined TARGET | Moxifloxacin and Dexamethasone combined | Federal University of São Paulo | phase 3 | Fluoroquinolone antibiotic + Corticosteroid combination | Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone) | |
| moxifloxacin / dexamethasone | moxifloxacin / dexamethasone | Federal University of São Paulo | marketed | Fluoroquinolone antibiotic + corticosteroid combination | Bacterial DNA gyrase, topoisomerase IV, glucocorticoid receptor | |
| Levofloxacin + dexamethasone followed by dexamethasone | Levofloxacin + dexamethasone followed by dexamethasone | NTC srl | phase 3 | Fluoroquinolone antibiotic + corticosteroid combination | Bacterial DNA gyrase, topoisomerase IV (levofloxacin); glucocorticoid receptor (dexamethasone) | |
| Ciprofloxacin HCl and Hydrocortisone | Ciprofloxacin HCl and Hydrocortisone | Farmoquimica S.A. | phase 3 | Fluoroquinolone antibiotic + corticosteroid combination | Bacterial DNA gyrase and topoisomerase IV; glucocorticoid receptor | |
| Moxifloxacin / Dexamethasone Ophthalmic Solution | Moxifloxacin / Dexamethasone Ophthalmic Solution | Laboratorios Sophia S.A de C.V. | phase 3 | Fluoroquinolone antibiotic + Corticosteroid combination | Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Fluoroquinolone antibiotic + Corticosteroid combination class)
- Federal University of São Paulo · 1 drug in this class
- Laboratorios Sophia S.A de C.V. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Moxifloxacin and Dexamethasone combined CI watch — RSS
- Moxifloxacin and Dexamethasone combined CI watch — Atom
- Moxifloxacin and Dexamethasone combined CI watch — JSON
- Moxifloxacin and Dexamethasone combined alone — RSS
- Whole Fluoroquinolone antibiotic + Corticosteroid combination class — RSS
Cite this brief
Drug Landscape (2026). Moxifloxacin and Dexamethasone combined — Competitive Intelligence Brief. https://druglandscape.com/ci/moxifloxacin-and-dexamethasone-combined. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab